CD276 and neoplasm: Recently, Li et al. tested a second-generation CAR specifically targeting B7-H3 and CD28 in PCa that was positive for B7-H3 and found that they efficiently controlled the growth of the tumor and increased the release of TNF-α and IFN-γ in vitro [104].